Precision BioSciences, Inc.
302 East Pettigrew Street
Durham
North Carolina
27701
United States
Tel: 919-314-5512
Fax: 480-393-5553
Website: http://www.precisionbiosciences.com/
About Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
Precision BioSciences: Culture
197 articles with Precision BioSciences, Inc.
-
Precision BioSciences Announces Change to its Board of Directors
11/10/2022
Precision BioSciences, Inc. today announced that Dr. Raymond Schinazi is stepping down from the company’s Board of Directors and will continue as a member of the company’s SAB, lending his deep expertise in antiviral drug discovery and development.
-
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
11/8/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
-
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - November 04, 2022
11/4/2022
Precision BioSciences, Inc. announced that, on November 2, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.
-
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
11/3/2022
Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that an abstract on the effective cell dose and functional attributes of the company’s lead CD19 candidate, Azercabtagene Zapreleucel (azer-cel) was accepted for poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 10-13, 2022 in New Orleans, Louisiana.
-
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022
11/2/2022
Precision BioSciences, Inc. today announced that it will publish financial results for the third quarter 2022 and provide a business update on November 8, 2022.
-
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
10/26/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso, President and Chief Executive Officer of Precision BioSciences (the “Company”) under the Company’s 2021 Employment Inducement Incentive Award Plan.
-
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress
10/11/2022
Precision BioSciences, Inc. announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre.
-
Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit
9/22/2022
Precision BioSciences, Inc. today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.
-
Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
-
Precision BioSciences Announces Senior Leadership Organizational Changes - Sep 02, 2022
9/2/2022
Precision BioSciences, Inc. announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team reporting to Michael Amoroso, Chief Executive Officer.
-
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update
8/8/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.
-
Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022
8/1/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022.
-
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 25, 2022
7/25/2022
Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, announced that, on July 19, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.
-
Precision BioSciences Announces Closing of Underwritten Offering of Common Stock
6/27/2022
Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share.
-
In addition to patent cases, partnerships and pledging money to global tropical disease efforts, Novartis scored a win on a combo-treatment for solid tumors.
-
Precision BioSciences and Novartis are teaming up to develop a potential cure for hemoglobinopathies such as sickle cell disease and beta-thalassemia.
-
Precision BioSciences Announces $50 Million Offering of Common Stock
6/21/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately $50.0 million.
-
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
6/21/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the “Agreement”).
-
Precision BioSciences' clinical program exploring allogeneic CAR T therapy may well produce a market pioneer after initial data showed its ability to deliver a 100% overall response rate.
-
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
6/8/2022
PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed Subjects.